Detection of Chemotherapy Induced Cardiotoxicity

George Washington University1 site in 1 country36 target enrollmentJanuary 2008

ConditionsCancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cancer
Sponsor: George Washington University
Enrollment: 36
Locations: 1
Primary Endpoint: The genetic profile of patients with anthracycline-induced elevation of troponin-I
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).

Detailed Description

To identify patients at risk of development of heart damage after receiving chemotherapy by obtaining the genetic profile of those who show: elevation of troponin, left ventricular systolic and diastolic dysfunction, and pro-oxidant stress markers.

Registry

clinicaltrials.gov

Start Date

January 2008

End Date

June 2012

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

George Washington University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•undergoing anthracycline and/or trastuzumab therapy for the first time

Exclusion Criteria

•abnormal ventricular ejection fraction
•past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension

Outcomes

Primary Outcomes

The genetic profile of patients with anthracycline-induced elevation of troponin-I

Time Frame: one year

Secondary Outcomes

Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction(one year)
Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile(one year)